Sanofi: Meningitis trials

The registry lists 42 Meningitis studies with Sanofi as lead sponsor. 0 are open to participants now and 39 have results posted.

Phase 1 1Phase 2 16Phase 3 12Phase 4 8No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in ToddlersCompletedNCT03205371Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT03205358Phase 2Results posted
• Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 YearsCompletedNCT03077438Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in ToddlersCompletedNCT02955797Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and OlderCompletedNCT02842866Phase 3Results posted
• Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02842853Phase 3Results posted
• Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02752906Phase 3Results posted
• Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in VietnamCompletedNCT02640404Phase 2Results posted
• Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years EarlierCompletedNCT02633787Phase 4Results posted
• Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult SubjectsCompletedNCT02591290Phase 4Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsCompletedNCT02199691Phase 2Results posted
• Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian FederationCompletedNCT01890759Phase 3Results posted
• Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and OlderCompletedNCT01732627Phase 2Results posted
• Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to ChildrenCompletedNCT01689155Results posted
• Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of AgeCompletedNCT01659996Phase 4Results posted
• Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South KoreaCompletedNCT01642589Phase 3Results posted
• Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese SubjectsCompletedNCT01519713Phase 3Results posted
• Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra VaccineCompletedNCT01442675Phase 2Results posted
• Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in ChildrenCompletedNCT01430611Phase 4Results posted
• Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine ImmunizationsCompletedNCT01359449Phase 3Results posted
• Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the PhilippinesCompletedNCT01270503Phase 4Results posted
• Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial VaccinationCompletedNCT01239043Phase 2Results posted
• A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in IndiaCompletedNCT01086969Phase 3Results posted
• A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and ToddlersCompletedNCT01049035Phase 2Results posted
• Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® VaccineCompletedNCT00862277Results posted
• Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®CompletedNCT00850603Phase 4Results posted
• Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in AdolescentsCompletedNCT00777790Phase 2Results posted
• Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap VaccineCompletedNCT00777257Phase 4Results posted
• Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy AdultsTerminatedNCT00772629Phase 2Results posted
• Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate VaccineCompletedNCT00772070Phase 2Results posted
• Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in ChildrenCompletedNCT00771849Phase 2Results posted
• 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year OldsCompletedNCT00728260Results posted
• Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26CompletedNCT00700713Phase 2Results posted
• Dose Comparison Study of Menactra® in US ChildrenCompletedNCT00700635Phase 2Results posted
• Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of AgeCompletedNCT00643916Phase 2Results posted
• Immunology and Safety of Menactra® in Children in Saudi ArabiaCompletedNCT00539032Phase 3Results posted
• Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®CompletedNCT00269477Phase 2Results posted
• Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®CompletedNCT00258856Phase 2Results posted
• Descriptive, Post-marketing, Surveillance Safety Study of Menactra VaccineCompletedNCT00254995Results posted
• Postmarketing Surveillance Study for Use of Menactra® in the Republic of KoreaCompletedNCT02864927Phase 4
• Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian FederationCompletedNCT02699840
• Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in ToddlersCompletedNCT00631995Phase 1